Related Experiment Videos
[Angioplasty of coronary arteries in chronic coronary insufficiency]
F Cherrier1, Y Juilliere, N Danchin
1Service de cardiologie B, Hémodynamiqiue diagnostique et interventionnelle, CHU Nancy-Brabois, Vandoeuvre-lès-Nancy.
Insights
Coronary angioplasty has advanced, treating more complex cases. However, challenges like restenosis and the need for more trials persist for chronic heart failure.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Context:
- Coronary angioplasty technology has significantly advanced over the last five years.
- Indications have expanded to include complex conditions like multiple vessel disease, chronic occlusions, and post-bypass lesions.
Purpose:
- To review the advancements and challenges associated with transluminal coronary angioplasty.
- To highlight the need for further research, particularly randomized trials, to define its role in chronic heart failure.
Summary:
- Transluminal coronary angioplasty has seen technological improvements, broadening its application.
- Despite initial success and low complication rates, issues such as restenosis, unexplained incidents, and cost remain.
- Newer techniques like atheroma excision are emerging but require evaluation.
Impact:
- Identifies key limitations and areas for improvement in current coronary angioplasty practices.
- Emphasizes the critical need for robust clinical trials to establish definitive indications for angioplasty in chronic heart failure.
- Suggests future research directions for advanced interventional cardiology techniques.
Abstract:
During the past five years transluminal angioplasty of the coronary arteries has considerably developed due to the improvement of the technology. Beside one-vessel lesions, its indications have been extended to multiple vessel pathology, chronic obturation and lesions found in patients who had previously undergone aorto-coronary bypass, as well as in those who had unstable angina, or in the elderly. Despite the quality of the initial results and the relatively low accident rate, this method has raised numerous problems: (I) unintentional optimization of the results, (II) unexplained postangioplastic incidents, (III) high rate of early restenosis, (IV) encouraging long-term results but marked by numerous coronary "events", (V) increasing cost of the procedure, (VI) disappointing resumption of work and, above all, (VII) lack of good randomized trials to establish the exact indications of angioplasty in the treatment of chronic heart failure. The new techniques of cardiocirculatory assistance or excision of atheroma have only started to be evaluated.